Common and rare variants in SLCO1B1 are associated with statin intolerance
Authors:
- Margherita BigossiMBMargherita Bigossi
- Cyrielle MaroteauCMCyrielle Maroteau
- Adem Y DawedADAdem Y Dawed
- Alasdair TaylorATAlasdair Taylor
- Sundararajan SrinivasanSSSundararajan Srinivasan
- Alaa’ Lufti MelhemAMAlaa’ Lufti Melhem
- Ewan R PearsonEPEwan R Pearson
- Roberto PolaRoberto Pola
- Colin N A PalmerCPColin N A Palmer
- Moneeza K SiddiquiMSMoneeza K Siddiqui
Preprint
Abstract
Background and Aims: The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1 , which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, will provide more reliable estimates of statin intolerance. Methods and Results: High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: OR GSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy OR SRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: OR SRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (OR Val174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; OR risk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HR Val174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HR risk-haplotypes 2.44 [95%CI:1.46, 4.08],pSLCO1B1 , in addition to Val174Ala, provides more reliable estimates of statin intolerance.Keywords
This publication has 34 references indexed in Scilit:
- Genomewide Association Study of Simvastatin PharmacokineticsClinical Pharmacology & Therapeutics, 2022
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal SymptomsClinical Pharmacology & Therapeutics, 2022
- Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and AtorvastatinClinical Pharmacology & Therapeutics, 2021
- An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2021
- Pharmacogenetics at Scale: An Analysis of the UK BiobankClinical Pharmacology & Therapeutics, 2020
- Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker–Induced AngioedemaClinical Pharmacology & Therapeutics, 2020
- Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performanceAtherosclerosis, 2013
- Optimal Unified Approach for Rare-Variant Association Testing with Application to Small-Sample Case-Control Whole-Exome Sequencing StudiesThe American Journal of Human Genetics, 2012
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJACC, 2009
- SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatinClinical Pharmacology & Therapeutics, 2006